OBJECTIVE： To investigate the clinical efficacy and safety of cilostazol combined with alprostadil in the treatment of peripheral arterial disease （PAD）. METHODS： A total of 68 PAD patients in our hospital from Jan. 2015 to Jan. 2016 were divided into observation group （34 cases） and control group （34 cases） according to random number table.  Control group was given basical treatment， and Alprostadil injection 2 mL+0.9％ Sodium chloride injection 100 mL， ivgtt， qd. Observation group was additionally given Cilostazol tablets 100 mg， po， bid， on the basis of control group. Both groups were treated for 30 days. Clinical efficacies of 2 groups were observed. The hemorheology indexes （hematocrit， whole blood high-shearing viscosity， erythrocyte aggregation index， erythrocyte deformation index， plasma viscosity）， inflammatory factor indexes （TNF-α， IL-6， IL-8

hs-CRP）， oxidation stress indexes （GSH-Px， SOD， T-Aoc， MDA）， arteriosclerosis indexes （ABI， TBI， dorsalis pedis artery blood flow） were determined before and after treatment. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group （91.18％） was significantly higher than that of control group （79.41％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in hemorheology indexes， inflammatory factors indexes， oxidant stress indexes or arteriosclerosis indexes between 2 groups （P＞0.05）. After treatment， hematocrit， whole blood high-shearing viscosity， erythrocyte aggregation index， erythrocyte deformation index， plasma viscosity， the levels of TNF-α， IL-6， IL-8， hs-CRP and MDA in 2 groups were decreased significantly； while the levels of GSH-Px， SOD， T-Aoc， ABI， TBI and dorsalis pedis artery blood flow were increased significantly； the improvement of above indexes in observation group was significantly better than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between observation group （14.71％） and control group （11.76％） （P＞0.05）. CONCLUSIONS： For PAD， cilostazol combined with alprostadil can effectively improve hemorheology indexes， inflammatory factor indexes， oxidation stress indexes and arteriosclerosis indexes with good safety.